215 related articles for article (PubMed ID: 22554404)
21. Pharmacovigilance for children's sake.
Star K; Edwards IR
Drug Saf; 2014 Feb; 37(2):91-8. PubMed ID: 24446277
[TBL] [Abstract][Full Text] [Related]
22. Adverse drug reactions.
Montané E; Santesmases J
Med Clin (Barc); 2020 Mar; 154(5):178-184. PubMed ID: 31771857
[TBL] [Abstract][Full Text] [Related]
23. Pharmacovigilance: Importance, concepts, and processes.
Kumar A
Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
[No Abstract] [Full Text] [Related]
24. Pharmacovigilance: methods, recent developments and future perspectives.
Härmark L; van Grootheest AC
Eur J Clin Pharmacol; 2008 Aug; 64(8):743-52. PubMed ID: 18523760
[TBL] [Abstract][Full Text] [Related]
25. [Understanding and reducing the risk of adverse drug reactions in pediatric patients].
Gotta V; van den Anker J; Pfister M
Ther Umsch; 2015 Dec; 72(11-12):679-86. PubMed ID: 26654811
[TBL] [Abstract][Full Text] [Related]
26. The adverse drug reaction reporting assignment for specialist oncology nurses: a preliminary evaluation of quality, relevance and educational value in a prospective cohort study.
Schutte T; van Eekeren R; Richir M; van Staveren J; van Puijenbroek E; Tichelaar J; van Agtmael M
Naunyn Schmiedebergs Arch Pharmacol; 2018 Jan; 391(1):17-26. PubMed ID: 29063137
[TBL] [Abstract][Full Text] [Related]
27. Artificial Intelligence for Drug Toxicity and Safety.
Basile AO; Yahi A; Tatonetti NP
Trends Pharmacol Sci; 2019 Sep; 40(9):624-635. PubMed ID: 31383376
[TBL] [Abstract][Full Text] [Related]
28. The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactions.
Clark DW; Harrison-Woolrych M
Curr Drug Saf; 2006 May; 1(2):169-78. PubMed ID: 18690928
[TBL] [Abstract][Full Text] [Related]
29. Evolving paradigms in pharmacovigilance.
Brewster W; Gibbs T; Lacroix K; Murray A; Tydeman M; Almenoff J
Curr Drug Saf; 2006 May; 1(2):127-34. PubMed ID: 18690923
[TBL] [Abstract][Full Text] [Related]
30. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
[TBL] [Abstract][Full Text] [Related]
31. Frequency, types, severity, preventability and costs of Adverse Drug Reactions at a tertiary care hospital.
Geer MI; Koul PA; Tanki SA; Shah MY
J Pharmacol Toxicol Methods; 2016; 81():323-34. PubMed ID: 27109493
[TBL] [Abstract][Full Text] [Related]
32. WHO strategy for collecting safety data in public health programmes: complementing spontaneous reporting systems.
Pal SN; Duncombe C; Falzon D; Olsson S
Drug Saf; 2013 Feb; 36(2):75-81. PubMed ID: 23329541
[TBL] [Abstract][Full Text] [Related]
33. Patient versus healthcare professional spontaneous adverse drug reaction reporting: a systematic review.
Inch J; Watson MC; Anakwe-Umeh S
Drug Saf; 2012 Oct; 35(10):807-18. PubMed ID: 22928729
[TBL] [Abstract][Full Text] [Related]
34. The monitoring medicines project: a multinational pharmacovigilance and public health project.
Pal SN; Olsson S; Brown EG
Drug Saf; 2015 Apr; 38(4):319-28. PubMed ID: 25829215
[TBL] [Abstract][Full Text] [Related]
35. Postmarketing surveillance.
Vlahović-Palčevski V; Mentzer D
Handb Exp Pharmacol; 2011; 205():339-51. PubMed ID: 21882120
[TBL] [Abstract][Full Text] [Related]
36. Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre.
Watson S; Chandler RE; Taavola H; Härmark L; Grundmark B; Zekarias A; Star K; van Hunsel F
Drug Saf; 2018 Feb; 41(2):203-212. PubMed ID: 28933055
[TBL] [Abstract][Full Text] [Related]
37. Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.
Montastruc JL; Sommet A; Lacroix I; Olivier P; Durrieu G; Damase-Michel C; Lapeyre-Mestre M; Bagheri H
Joint Bone Spine; 2006 Dec; 73(6):629-32. PubMed ID: 17110152
[No Abstract] [Full Text] [Related]
38. Pharmacoepidemiologic research in Australia: challenges and opportunities for monitoring patients with rheumatic diseases.
Lu CY
Clin Rheumatol; 2009 Apr; 28(4):371-7. PubMed ID: 19190976
[TBL] [Abstract][Full Text] [Related]
39. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
40. The role of the clinical pharmacologist in the management of adverse drug reactions.
Moore N
Drug Saf; 2001 Jan; 24(1):1-7. PubMed ID: 11219484
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
